Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day+100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?

Medeni S. S., Acar C., Olgun A., Acar A., Seyhanli A., Taskiran E., ...Daha Fazla

CLINICAL TRANSPLANTATION, cilt.32, sa.9, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 9
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1111/ctr.13359
  • Dergi Adı: CLINICAL TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Monocyte Lymphocyte Ratio (MLR), Multiple myeloma, Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), POOR-PROGNOSIS, INFLAMMATION, CANCER, MICROENVIRONMENT, SURVIVAL, IMPROVES, AGENTS, INDEX
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Background: Recent reports have showed that neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are predictors of progression-free survival (PFS) and overall survival (OS) in many types of cancer. This study evaluates the predictive value of NLR, MLR, and PLR for survival in MM patients treated with to ASCT.